Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

haploidentical natural killer cells K-NK002

A population of ex-vivo expanded and activated haploidentical donor-derived natural killer (NK) cells, with potential immunomodulating and antineoplastic activities. Upon administration prior to and following haploidentical hematopoietic cell transplantation, the haploidentical NK cells K-NK002 may induce an anti-tumor immune response and may exert cytotoxicity against tumor cells.

Check for active clinical trials using this agent View this agent in the NCI Thesaurus

Synonym:	haploidentical NK cells K-NK002 haploidentical NKs K-NK002 NK cells K-NK002
Code name:	K-NK 002 K-NK-002

haploidentical natural killer cells K-NK002

Search NCI's Drug Dictionary